Link to Full Article Cambridge, UK., 9th July 2019: Arecor Ltd (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company. Under this […]

Link to Full Article Cambridge, UK., 7th May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting […]

Hot on the heels of our first clinical trials approval, Arecor is delighted to be listed in Business Weekly’s ‘Killer50’, as a leading lifescience innovator. Please see the listing and feature here on Page 12: Link

Cambridge (UK), 11th March 2019, Arecor Limited (‘Arecor’ or the ’Company’), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect […]

ARECOR LIMITED (“Arecor” or “the Company”) ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Cambridge, UK., 5 December 2018: Arecor Ltd (“the Company”), the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah […]